The multi-site trial has enrolled 457 patients to evaluate the safety and efficacy of TNX-102 SL to manage fibromyalgia. Credit: Agenturfotografin / Shutterstock.

Tonix Pharmaceuticals has concluded the Phase III RESILIENT study’s clinical phase of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6mg to manage fibromyalgia.

The double-blind, placebo-controlled, registration-quality and multi-site trial has enrolled 457 patients to evaluate the safety and efficacy of TNX-102 SL in managing this condition.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This two-arm study randomised subjects across 33 sites in the US.

The initial two weeks of treatment include a run-in period in which subjects begin on TNX-102 SL 2.8mg (one tablet) dose or placebo.

Later, all participants increased their dose to TNX-102 SL 5.6mg or two placebo tablets for the remaining 12 weeks.

See Also:

Daily diary pain severity score change to week 14 from baseline for TNX-102 SL 5.6mg against placebo is the trial’s primary endpoint. It will be analysed by mixed model repeated measures with multiple imputations.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topline results from the trial are anticipated by the end of December.

If successful, RESILIENT is anticipated to serve as the final, well-controlled efficacy trial required for submitting a new drug application (NDA) to receive approval from the US Food and Drug Administration (FDA).

Tonix Pharmaceuticals CEO Seth Lederman said: “TNX-102 SL is a centrally-acting, non-opioid analgesic bedtime medication designed to be used on a chronic basis for the management of fibromyalgia.

“We believe TNX-102 SL works by improving sleep quality, which leads to improvement of other symptoms. In previous studies, TNX-102 SL showed broad coverage across the symptoms of fibromyalgia, including chronic widespread pain, fatigue and sleep disturbance.”